Johnson & Johnson’s Shockwave C2 Aero Fly Coronary IVL Catheter Launched in United States

October 20, 2026—Johnson & Johnson announced the United States launch of its Shockwave C2 Aero Fly coronary intravascular lithotripsy (IVL) catheter, which is designed to treat a broad range of calcified coronary artery lesions.

According to the company, this next-generation coronary IVL catheter leverages Shockwave IVL’s differentiated mechanism of action and builds on improvements delivered in the Shockwave C2 Aero platform.

Johnson & Johnson stated that pulses are delivered at 2 Hz to cut treatment time in half: 115 seconds versus 230 seconds with previous generations of IVL. Pause times between pulsing cycles are cut to 5 seconds, shortening wait times between cycles by 50%.

Hector Tamez Aguilar, MD, and Karim Al-Azizi, MD, commented on the Shockwave C2 Aero Fly in the company’s press release.

“In the cath lab, every second matters, especially as we see more complex cases and higher procedure volumes,” stated Dr. Aguilar, an interventional cardiologist at Piedmont Healthcare in Atlanta, Georgia. “By delivering pulses twice as fast and decreasing pause time between cycles, Shockwave C2 Aero Fly enables faster workflows, helping physicians treat calcified coronary disease more efficiently while meeting the growing pace and demand of cath labs.”

Dr. Al-Azizi added, “During IVL treatment, balloon inflation temporarily blocks blood flow, and that time matters for patient care. Shockwave C2 Aero Fly raises the bar for coronary interventions by making procedures easier for physicians and less strenuous for patients. Its shorter balloon inflation and pause time reduce ischemic time and related symptoms for patients, enabling better, quicker, and more streamlined care.” Dr. Al-Azizi is Medical Director, Structural Heart Program and Cardiac Catheterization Laboratories at Baylor Scott & White Health in Plano, Texas.